Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer

Recruiting now

Conditions studied: Endometrial Carcinoma Stage I, Atypical Endometrial Hyperplasia

In brief

To construct a prediction model of progesterone sensitivity in patients with endometrial cancer treated with fertility preservation

Key facts

Study ID

NCT05647109

Run by

Peking University People's Hospital

People needed

244

Starts

2021-09-01

Expected to finish

2025-10-31

Last updated by the study team

2025-05-04

Who can join

Age: 17 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Have a confirmed pathological diagnosis based upon hysteroscopy: atypical endometrial hyperplasia or histologically prove well-differentiated EEC G1 without myometrial invasion
• No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound
• Have a desire for remaining reproductive function or uterus
• Good compliance with adjunctive treatment and follow-up

You may not qualify if…

• Acute liver disease or liver tumor (benign or malignant) or renal dysfunction
• Pregnancy or potential pregnancy
• Confirmed diagnosis of any cancer in reproductive system
• Acute severe disease such as stroke or heart infarction or a history of thrombosis disease
• Hypersensitivity or contradiction for using MPA or MA
• With other factors of reproductive dysfunction;
• Strong request for uterine removal or other conservative treatment

Where it is running

• Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.